Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to $2.8 million.

  • Traws Pharma's Accumulated Expenses rose 498.11% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 498.11%. This contributed to the annual value of $3.1 million for FY2024, which is 752.59% down from last year.
  • According to the latest figures from Q3 2025, Traws Pharma's Accumulated Expenses is $2.8 million, which was up 498.11% from $2.6 million recorded in Q2 2025.
  • Over the past 5 years, Traws Pharma's Accumulated Expenses peaked at $4.1 million during Q1 2023, and registered a low of $2.5 million during Q1 2025.
  • In the last 5 years, Traws Pharma's Accumulated Expenses had a median value of $3.1 million in 2024 and averaged $3.1 million.
  • Per our database at Business Quant, Traws Pharma's Accumulated Expenses tumbled by 3688.03% in 2021 and then surged by 5776.92% in 2023.
  • Over the past 5 years, Traws Pharma's Accumulated Expenses (Quarter) stood at $3.1 million in 2021, then grew by 26.44% to $4.0 million in 2022, then decreased by 14.77% to $3.4 million in 2023, then decreased by 7.53% to $3.1 million in 2024, then dropped by 10.86% to $2.8 million in 2025.
  • Its Accumulated Expenses was $2.8 million in Q3 2025, compared to $2.6 million in Q2 2025 and $2.5 million in Q1 2025.